SCHEMBL3012800

SCHEMBL3012800

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(C)cc(C)c4)cs3)CC2)cc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
MAPT P10636 1/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
HTT P42858 2/20 0.36
POLB P06746 2/20 0.36
TSHR P16473 2/20 0.36
DNM1L O00429 1/20 0.36
AVPR1B P47901 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
TP53 P04637 1/20 0.35
F2RL3 Q96RI0 3/20 0.35
HSD11B1 P28845 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002775 0.93 KDM4E (0.40) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3005141 0.92 HTT (0.39) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3014450 0.92 KDM4E (0.41) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3007606 0.91 KDM4E (0.40) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3015109 0.91 KDM4E (0.40) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3016704 0.91 KDM4E (0.44) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3006623 0.90 KDM4E (0.39) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3013286 0.90 KDM4E (0.39) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3009492 0.90 POLB (0.41) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3018931 0.89 KDM4E (0.39) KDM4ESMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM4E 4398/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.